Zolpidem

Czym jest Zolpidem?

Zolpidem is a non-benzodiazepine hypnotic medicine — commonly referred to as a Z-drug — used for the short-term treatment of insomnia, particularly where difficulty falling asleep is the primary complaint. It is available under several brand names across Europe, including Stilnoct and Sanval.

Zolpidem belongs to the imidazopyridine chemical class but shares a similar mechanism of action with benzodiazepines, acting on GABA-A receptors. However, its receptor subtype selectivity is considered to confer a somewhat different pharmacological profile, including comparatively less muscle relaxation and anxiolysis compared to classical benzodiazepines.

Jak działa Zolpidem work?

Zolpidem selectively enhances the activity of gamma-aminobutyric acid (GABA) at the GABA-A receptor complex by binding preferentially to the alpha-1 subunit. This receptor subtype is associated with sedation and hypnosis, which explains why zolpidem’s primary effects are sleep-promoting with relatively less muscle relaxation and anti-anxiety activity compared to classical benzodiazepines.

The result is:

• Reduced sleep onset latency: Patients fall asleep faster
• Increased total sleep time: Particularly in the earlier part of the night
• Minimal disruption to sleep architecture: Zolpidem is considered to preserve normal sleep stages better than some longer-acting hypnotics

Zolpidem has a short half-life of approximately 2.4 hours (slightly longer in older adults and women), which is designed to allow sleep onset without excessive next-morning sedation.

Dla kogo jest Zolpidem for?

Zolpidem is indicated for the short-term treatment of insomnia in adults. It is particularly suited to sleep onset insomnia (difficulty falling asleep) rather than sleep maintenance insomnia (waking during the night), given its relatively short duration of action.

Clinical guidelines consistently recommend non-pharmacological interventions — in particular, Cognitive Behavioural Therapy for Insomnia (CBT-I) — as the primary treatment for chronic insomnia. Zolpidem and other hypnotics are recommended only where:

• CBT-I is unavailable or has been inadequate
• The insomnia is acute and significantly impairing functioning
• There is a clear short-term indication

Zolpidem is not appropriate for:

• People with sleep apnoea syndrome
• Those with myasthenia gravis or severe respiratory insufficiency
• People with significant liver impairment
• Those with a history of alcohol or substance dependence
• Pregnant or breastfeeding women

Dawkowanie

Zolpidem is taken orally as a tablet, immediately before going to bed. A full 7–8 hours of sleep should be available before any activities requiring alertness.

Group	Recommended Dose	Notes
Adult women	5 mg at bedtime	Lower dose due to slower clearance
Adult men	5–10 mg at bedtime	May increase to 10 mg if 5 mg insufficient
Adults over 65	5 mg at bedtime	Start low; increased sensitivity
Maximum recommended duration	2–4 weeks	Including tapering period

The EMA updated its guidance on zolpidem dosing to recommend that women start at 5 mg due to evidence of higher morning blood concentrations and associated driving impairment risk.

Skutki uboczne

Częste skutki uboczne (mogą dotyczyć więcej niż 1 na 10 osób)

• Drowsiness or somnolence the following day
• Headache
• Dizziness
• Nausea
• Anterograde amnesia (difficulty forming new memories after taking the medicine)

Serious risks

• Complex sleep behaviours: Sleep-walking, sleep-driving, sleep-eating with no memory of events — risk is higher at doses above recommended levels and when combined with alcohol or CNS depressants
• Next-morning impairment: Driving impairment may persist into the morning even after a full night’s sleep, particularly in women, older adults, or those taking higher doses
• Dependence and withdrawal: Particularly with use beyond the recommended treatment period
• Rebound insomnia: Temporary worsening of sleep upon stopping treatment
• Hallucinations and psychiatric reactions: Including confusion, agitation, and hallucinations, particularly in older adults
• Falls: Due to sedation and impaired coordination during the night

Zolpidem a alternatywy

Medicine	Class	Primary Indication	Half-Life	Rx Required
Zolpidem	Z-drug	Sleep onset insomnia	~2–3 hours	Yes
Zopiclone	Z-drug	Sleep onset and maintenance	~5–6 hours	Yes
Lormetazepam	Benzodiazepine	Severe insomnia	~10–12 hours	Yes
Melatonin	Hormone	Circadian disruption, jet lag	~1–2 hours	Low dose: No
Diphenhydramine	Antihistamine	Occasional mild insomnia	~9 hours	No

Zopiclone may offer an advantage over zolpidem for patients with both sleep onset and sleep maintenance difficulties, given its longer half-life. A doctor is best placed to determine which option is most clinically appropriate for individual patients.

Jak uzyskać dostęp do sleep treatment online w Europie

Zolpidem is a prescription-only controlled medicine across all państwach członkowskich UE. It cannot be legally dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary: our platform connects patients with independent EU-registered doctors who can conduct confidential online health assessments. We do not prescribe medicines, employ doctors, or dispense medicines directly.

The process is:

1. Wypełnij ocenę stanu zdrowia: Provide a structured health history, including details of your sleep difficulties, current medications, and relevant medical history.
2. Ocena lekarska: An independent EU-registered doctor reviews your assessment. If a prescription sleep medicine is clinically appropriate, they may issue a prescription.
3. Recepta i realizacja: If a prescription is issued, it is forwarded to a licensed EU pharmacy partner for dispensing and delivery.

Important: Prescrivia nie gwarantuje that a prescription will be issued. All clinical decisions are made independently by qualified medical professionals.

Ważne informacje dotyczące bezpieczeństwa

Do not take Zolpidem if you have:

• Sleep apnoea syndrome
• Myasthenia gravis
• Severe respiratory insufficiency or liver disease
• A history of alcohol or drug dependence

Driving and machinery: Do not drive, cycle, or operate machinery after taking zolpidem. Morning impairment may persist into the following day, particularly in women and older adults. The EMA warns that zolpidem blood concentrations can remain above levels that impair driving ability for 7–8 hours after a 10 mg dose.

Alcohol: Never combine zolpidem with alcohol — the combination significantly enhances sedation and substantially increases the risk of complex sleep behaviours.

Źródła

Medical information on this page is based on the following sources:

• Europejska Agencja Leków (EMA). Questions and answers on zolpidem-containing medicines. EMA/CHMP/742257/2013.
• Europejska Agencja Leków (EMA). Assessment report on zolpidem. EMEA/H/A-31/1401.
• Światowa Organizacja Zdrowia (WHO). Management of sleep disorders — WHO guidelines. who.int

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.